1. Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model
   Bo Chen et al, 2020, Frontiers in Pharmacology CrossRef
2. Design of Hepatic Targeted Drug Delivery Systems for Natural Products: Insights into Nomenclature Revision of Nonalcoholic Fatty Liver Disease
   Rou Tang et al, 2021, ACS Nano CrossRef
3. Beta vulgaris L. (Beetroot) Methanolic Extract Prevents Hepatic Steatosis and Liver Damage in T2DM Rats by Hypoglycemic, Insulin-Sensitizing, Antioxidant Effects, and Upregulation of PPARα
   Laila Naif Al-Harbi et al, 2021, Biology CrossRef
4. SOAT2, a new target of intestinal lipid-lowering drugs, mediates lipid uptake inhibition and lipid-lowering effects
   Jingjia Liang et al, 2023, Chinese Science Bulletin CrossRef
5. The protection afforded by Berberine against chemotherapy‐mediated nephropathy in rats involves regulation of the antioxidant axis
   Reham I. Alagal et al, 2023, Basic & Clinical Pharmacology & Toxicology CrossRef
6. SGL 121 Attenuates Nonalcoholic Fatty Liver Disease through Adjusting Lipid Metabolism Through AMPK Signaling Pathway
   Da Eun Kim et al, 2020, International Journal of Molecular Sciences CrossRef
7. Molecular updates on berberine in liver diseases: Bench to bedside
   Sapana Bansod et al, 2021, Phytotherapy Research CrossRef
8. Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease
   Longxin Qiu et al, 2020, Current Drug Targets CrossRef
9. Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects
   Marina Galicia-Moreno et al, 2020, Antioxidants CrossRef
10. Baicalin attenuated metabolic dysfunction‐associated fatty liver disease by suppressing oxidative stress and inflammation via the p62–Keap1–Nrf2 signalling pathway in db/db mice
    Wen‐Jing Liu et al, 2023, Phytotherapy Research CrossRef
11. The place of berberine in the treatment of metabolic syndrome
    E. V. Shrayner et al, 2024, Experimental and Clinical Gastroenterology CrossRef
12. Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies
    Sichen Ren et al, 2021, Frontiers in Pharmacology CrossRef
13. Mechanism Involved in Fortification by Berberine in CDDP-Induced Nephrotoxicity
    Vipin K. Verma et al, 2020, Current Molecular Pharmacology CrossRef
14. Berberine mitigates acetamiprid-induced hepatotoxicity and inflammation via regulating endogenous antioxidants and NF-κB/TNF-α signaling in rats
    Annu Phogat et al, 2023, Environmental Science and Pollution Research CrossRef
15. Biological targets of berberine hydrochloride and the mechanisms by which it alleviates metabolic-associated fatty liver disease
    Jingjia Liang et al, 2023, Chinese Science Bulletin CrossRef
16. Literature Review on the Use of Herbal Extracts in the Treatment of Non- Alcoholic Fatty Liver Disease
    Yutian Wang et al, 2022, Endocrine, Metabolic & Immune Disorders - Drug Targets CrossRef